ᑐᓂᔾᔪᑎᒋᓂᖅ ᐊᔪᕐᓇᖅᑐᖅ

ᐊᓴᐱ (HIV) ᐱᓕᕆᐊᖕᒍᒃᐸᑦ ᓄᖅᖃᖅᑎᑦᑎᖃᑦᑕᖅᑐᖅ ᐊᓴᐱᒥᒃ (HIV) ᑐᓂᔾᔪᑎᒋᔭᐅᓂᖓ

ᐊᓴᐱ (HIV) ᑐᓂᔾᔪᑎᒋᓂᖅ ᐊᔪᖅᑐᖅ ᑯᔭᖕᓂᒃᑯᑦ ᐃᓄᒃ ᐊᓴᐱᖃᖅᑐᖅ (HIV) ᐱᓕᕆᐊᖕᒍᒃᐸᑦ ᐊᒻᒪᓗ ᐊᖕᒋᑎᒋᓂᖓ ᐊᓴᐱ (HIV) ᐊᐅᖓᓃᑦᑐᖅ ᐊᑦᑎᒃᑑᖕᒋᓐᓇᖅᐸᑦ.

ᐊᓴᐱ (HIV) ᐱᓕᕆᐊᖕᒍᓂᖅ ᐊᑦᑎᒃᓯᑎᑦᑎᒃᐸᑦ ᐊᖕᒋᑎᒋᓂᖓᓂᒃ ᐋᓐᓂᐊᕐᓇᐅᑉ ᐊᐅᖓᓃᑦᑐᒥᑦ ᑐᖕᒐᓄᑦ 200 ᐊᔾᔨᖕᒋᓐᓂᒃ ᐊᑐᓂ ᒥᓕᓖᑕ ᐊᐅᖕᒥᑦ, ᑕᐃᔭᐅᔪᖅ **ᓄᖅᖃᖕᒐᑎᑕᐅᔪᖅ-ᒥᑦ.** ᑭᓇᑐᐃᓐᓇᖅ ᐋᓐᓂᐊᕐᓇᕐᒥᒃ ᓄᖅᖃᖕᒐᑎᑕᐅᔪᖅᖃᖅᐸᑦ, ᑐᓂᔾᔪᑎᒋᓂᖅ ᐊᔪᖅᑕᖕᒐ ᐊᓴᐱᒥᒃ (HIV) ᐊᓯᖕᒋᓐᓄᑦ ᑯᔭᒡᓗᑎᒃ.[1,2,3,4,5,6]

ᐋᓐᓂᐊᕐᓇᖅ ᓄᖅᖃᖕᒐᑎᑕᐅᔪᖅ

ᑐᖕᒐᓃᑉᐸᑦ **200** ᐊᔾᔨᖕᒋᑦ ᐊᑐᓂ ᒥᓕᓖᑕ ᐊᐅᖕᒥᑦ

ᖃᐅᔨᒐᒃᓴᐅᖕᒋᑉᐸᑦ = ᑐᓂᔾᔪᑎᒋᔭᒃᓴᐅᖕᒋᑦᑐᖅ (U=U)

U=U ᑐᓴᖅᑎᑦᑎᔪᖅ ᓴᖅᕿᑕᐅᓚᐅᖅᑐᖅ ᑕᑯᒃᓴᐅᑎᓐᓂᐊᕐᓗᒍ ᖃᐅᔨᓇᓱᒃᑐᓕᕆᓂᖅ ᑕᑯᒃᓴᐅᑎᑦᑎᔪᖅ **ᐊᓴᐱ (HIV) ᐱᓕᕆᐊᖕᒍᒃᐸᑦ ᑐᓂᓯᔪᖕᓇᖕᒋᑦᑐᑦ ᐊᓴᐱᒥᑦ (HIV) ᑯᔭᖕᓂᒃᑯᑦ.**

ᖃᐅᔨᒐᒃᓴᐅᖕᒋᑉᐸᑦ ᐋᓐᓂᐊᕐᓇᐅᑉ ᐊᖕᒋᑎᒋᓂᖓ ᑐᑭᖃᖅᑐᖅ ᓇᓃᓐᓂᕆᔭᖓ ᐊᓴᐱ (HIV) ᐃᓄᑉ ᐊᐅᖓᓂᑦ ᐊᑦᑎᒃᑑᔪᖅ **ᑕᑯᒃᓴᐅᔾᔭᖕᒋᕐᓗᓂ ᐊᑐᖅᑕᐅᕙᒃᑐᒃᑯᑦ ᖃᐅᔨᓴᖅᑕᐅᒃᐸᑦ.**

ᐱᐅᓯᕙᓪᓕᐊᓂᖕᒋᓐᓄᑦ ᐆᒃᑐᕋᐃᓃᑦ, ᐊᖕᒋᑎᒋᓪᓚᑦᑖᕐᓂᖓ ᐊᓴᐱ (HIV) "ᖃᐅᔨᒐᒃᓴᐅᖕᒋᕐᓗᓂ" ᐊᓯᐊᖕᒍᖅᐸᓪᓕᐊᖕᒋᓐᓇᕈᓐᓇᖅᑐᖅ, ᑕᐃᒪᓐᓇᒧᑦ ᐱᒻᒪᕆᐅᔪᖅ ᖃᐅᔨᒪᓗᓂ **ᓱᓇᑐᐃᓐᓇᐃᑦ ᐆᒃᑐᕋᐃᓂᕐᒥᑦ ᖃᓄᐃᖕᒐᓂᐅᔪᑦ ᑕᑯᒃᓴᐅᑎᑦᑎᔪᑦ ᐊᑦᑎᖕᓂᖅᓴᐅᔪᒥᒃ 200 ᐊᔾᔨᖕᒋᑦ ᐊᑐᓂ ᒥᓕᓖᑕ ᐊᐅᖕᒦᑦᑐᒥᑦ ᑐᑭᖃᖅᑐᖅ ᐊᓴᐱ (HIV) ᑐᓂᔾᔪᑎᒋᔭᐅᓂᖅ ᐊᔪᕐᓇᖅᑐᖅ.**

ᐋᓐᓂᐊᕐᓇᐅᑉ ᐊᖕᒋᑎᒋᓂᖓ

ᐱᔾᔪᑎᖃᖅᑐᖅ ᐊᖕᒋᑎᒋᓂᖓ ᐊᓴᐱ (HIV) ᐊᐅᖕᒦᑦᑐᖅ. ᐋᓐᓂᐊᕐᓇᐅᑉ ᐊᖕᒋᑎᒋᓂᖓᓂᒃ ᐆᒃᑐᕋᐃᖃᑦᑕᕐᓂᖅ 4-ᓂᑦ ᐊᕐᕕᓂᓖᑦ ᑕᖅᕿᑕᒫᒃᑯᑦ ᖃᐅᔨᒪᔾᔪᑎᑐᐊᖕᒍᔪᖅ ᐃᓄᒃ ᑎᑭᐅᑎᓯᒪᖕᒪᖔᑦ **ᐋᓐᓂᐊᕐᓇᖅ ᓄᖅᖃᖕᒐᑎᑕᐅᔪᖅ-ᒥᑦ.**

ᑐᑭᓯᐅᒪᔾᔪᑎᒃᑲᓐᓂᕐᓂᒃ ᐱᔪᒪᒍᕕᑦ, ᐅᕗᙱᕐᓗᑎᑦ Canada.ca/HIV.

ᐊᓴᐱ (HIV) ᐱᓕᕆᐊᖕᒍᖔᖕᒐᑦ ᐃᑲᔪᑐᐃᓐᓇᖅᑐᑦᑐᖅ ᐃᓄᖕᓂᒃ ᐊᓴᐱᖃᖅᑐᓂᑦ (HIV) ᐋᓐᓂᐊᖃᖅᑕᐃᓕᒪᓂᖕᒋᑦ ᖃᓄᐃᖕᒋᑦᑎᐊᕐᓗᑎᒃ, ᑭᓯᐊᓂ ᐊᓴᐱᒥᒃ (HIV) ᑐᓂᓯᑎᑦᑎᙱᒥᔪᖅ ᐊᓯᖕᒋᓐᓄᑦ.

1. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. ᐊᓴᐱ-1-ᒥᒃ (HIV) ᐋᓐᓂᐊᕐᓇᖅᑕᐃᓕᑎᑦᑎᖃᑦᑕᖅᑐᖅ ᐱᒋᐊᖅᓵᓕᓗᓂ ᐱᓕᕆᐊᖕᒍᓂᖓ antiretroviral-ᒥᑦ. ᓂᐅ ᐃᓐᓚᓐ ᑎᑎᖅᖃᐅᑎ ᐃᑦᒐᓄᑦ (The New England Journal of Medicine) 2011;365(6):493-505.
2. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. ᐱᓕᕆᐊᖕᒍᓂᖓ antiretroviral-ᒧᑦ ᑐᓂᓯᑦᑕᐃᓕᑎᑦᑎᓂᕐᒧᑦ ᐊᓴᐱ-1-ᒥᒃ (HIV). ᓂᐅ ᐃᓐᓚᓐ ᑎᑎᖅᖃᐅᑎ ᐃᑦᒐᓄᑦ (The New England Journal of Medicine) 2016;375(9):830-839.
3. Rodger AJ, Cambiano V, Bruun T, Vernazza P, Collins S, van Lunzen J, et al. ᑯᖃᑦᑕᕐᓗᓂ ᐅᓯᑉ ᐳᖓᓂᒃ ᐊᑐᖃᑦᑕᖅᓱᓪᓗᓂ ᐊᒻᒪᓗ ᐅᓗᕆᐊᓇᕐᓂᖅ ᐊᓴᐱᒥᒃ (HIV) ᑐᓂᓯᓂᖅ ᐋᓐᓂᐊᖃᖅᑐᒥᑦ ᐋᓐᓂᐊᖃᖅᖠᑦᑐᒧᑦ ᐱᖃᑎᒌᓂᑦ ᐃᒪᓐᓇᐃᑦᑐᖅᐊᓴᐱᒥᒃ (HIV) ᐱᖃᖅᑐᖅ ᐱᖃᑎᒋᔭᐅᔪᖅ ᐊᑐᖅᓗᓂ ᓄᖅᖃᖕᒐᑎᑦᑎᔪᒥᒃ ᐱᓕᕆᐊᖕᒍᕐᓗᓂ antiretroviral-ᒥᑦ. JAMA. 2016;316(2):171-181.
4. Rodger AJ, Cambiano V, Bruun T, Vernazza P, Collins S, Degen O, et al. ᐅᓗᕆᐊᓇᕐᓂᖅ ᐊᓴᐱᒥᒃ (HIV) ᑐᓂᔾᔪᑎᖃᕐᓂᕐᒧᑦ ᐅᓯᑉ ᐳᖓᓂᒃ ᐊᑐᖅᓱᓪᓗᓂ ᑯᔭᖕᓂᒃᑯᑦ ᐋᓐᓂᐊᖃᖅᑐᒥᑦ ᐋᓐᓂᐊᖃᖅᑎᑦᑐᒧᑦ ᐊᖑᑏᑦᓈᖕᓄᑦ ᐊᓴᐱᖃᖅᓱᓂ (HIV) ᐱᖃᑎᒋᔭᖕᒐ ᐊᑐᖅᓱᓂ ᓄᖅᖃᖕᒐᑎᑦᑎᔪᒥᒃ ᐱᓕᕆᐊᖕᒍᕐᓗᓂ antiretroviral-ᒥᑦ: ᑭᖑᓪᓕᖅᐹᒃᑯᑦ ᖃᓄᐃᖕᒐᓂᐅᔪᑦ ᖃᐅᔨᓴᐃᖅᑕᐅᔪᒥᑦ. ᓛᓐᓴᑦ (Lancet). 2019;393(10189):2428-2438.
5. Bavinton BR, Pinto AN, Phanuphak N, Grinsztejn B, Prestage GP, Zablotska-Manos IB, et al. ᐋᓐᓂᐊᕐᓇᕐᒥᒃ ᓄᖅᖃᖕᒐᑎᑦᑎᔪᖅ ᐊᒻᒪᓗ ᐊᓴᐱᒥᒃ (HIV) ᑐᓂᔾᔪᑎᖃᕐᓂᖅ ᐋᓐᓂᐊᖃᖅᑐᒥᑦ ᐋᓐᓂᐊᖃᖅᑎᑦᑐᒧᑦ ᐊᖑᑏᑦᓈᒃ ᐱᖃᑎᒌᒃᑐᓄᑦ:ᓄᓇᕐᔪᐊᕐᒥᑦ, ᕿᓂᖅᑐᑦ, ᖃᐅᔨᓴᖅᑐᑦ, ᐊᑕᐅᑦᑎᑯᑦ ᐊᓯᖕᒋᑦ ᐱᖃᑎᒌᒃᐅᑉᓗᑎᒃ ᖃᐅᔨᓴᐃᓂᖅ. ᓛᓐᓴᑦ (Lancet) ᐊᓴᐱ (HIV). 2018;5(8):e438-e447.
6. LeMessurier, J., Traversy, G., Varsaneux, O., Weekes, M., Avey, M. T., Niragira, O., … & Rodin, R. (2018). ᐅᓗᕆᐊᓇᕐᓂᖅ ᑯᔭᓗᓂ ᑐᓂᔾᔪᑎᖃᕐᓂᖅ ᐃᓄᐃᑦ ᐋᓐᓂᐊᓄᑦ ᐅᓇᑕᕈᑎᕐᓕᓂᑦ ᐋᖅᕿᐅᒪᖕᒋᑎᑦᑎᔪᖅ ᐋᓐᓂᐊᕐᓇᖅᐊᑐᕐᓗᓂ ᓄᖅᖃᖕᒐᑎᑦᑎᔪᒥᒃ ᐱᓕᕆᐊᖕᒍᕐᓗᓂ antiretroviral-ᒥᑦ, ᓄᖅᖃᖕᒐᑎᑦᑎᓗᓂ ᐋᓐᓂᐊᕐᓇᐅᑉ ᐊᕐᑎᑎᒋᓂᖕᒐᓂᑦ ᐊᒻᒪᓗ ᐅᓗᕆᐊᓇᕐᓂᖅ ᐊᑐᕐᓗᓂ: ᕿᒥᕐᔭᐅᔭᐅᖃᑦᑕᖅᑐᖅ. Cmaj, 190(46), E1350-E1360.

© ᐊᕐᒋᔪᖅᖃᔪᐊᖅ ᑭᑦ ᑲᓇᑕᒧᑦ, ᑭᒻᒪᖅᑐᖅᑕᐅᓂᖕᒐᑐᑦ ᒥᓂᔅᑕᒧᑦ ᐋᓐᓂᐊᓯᐅᖅᑎᓄᑦ, 2024 ᐅᖃᓕᒫᒐᐅᑉ ᓈᓴᐅᑎᖓ: 230872 | ᑎᑭᒡᒃᓂᑦ ᓈᓴᐅᑎᖓ: H14-465/2023Iku4-PDF | ISBN: 978-0-660-70632-0 (PDF)

Public Health Agency of Canada
Agence de la santé publique du Canada

ᐃᓕᑦᑎᖃᓐᓂᕆᑦ
Canada.ca/HIV Canada.ca/VIH

Canada